tbuckley/cabot-search huggingface dataset:
Intermediate Dose Melphalan, Bortezomib, Thalidomide, Dexametasone (MVTD) Conditioning Therapy and ASCT in Relapsed Multiple Myeloma Patients: A Single Center Experience.
Authors: Potito Rosario Scalzulli, Maria Rosa Valvano, Carlo C. Bodenizza, Angelo Michele Carella, Matteo M. Dell’Olio, Antonietta A.P. Falcone, Michele Mario Greco, Antonio A. La Sala, Francesco F.S. Mantuano, Lorella L. Melillo, Emanuela E. Merla, Michele M. Nobile, Sanpaolo G. Sanpaolo, Nicola N. Cascavilla
Journal: Blood (2007)
T Cell Receptor Vbeta Repertoire Plays An Important Role In Graft-Versus-Leukemia Effect To Acute Lymphocytic Leukemia With TCF3-PBX1
Authors: Yoko Oka, Ryosuke Shirasaki, Takuji Matsuo, Haruko Tashiro, Jun Ooi, Naoki Shirafuji
Journal: Blood (2013)
Elevated Interleukin-10 and “Disappearing HDL Syndrome” in Lymphoproliferative Disorders
Authors: Andreas Moriaitis, Lita Freeman, Robert Shamburek, Robert Wesley, Wyndham H. Wilson, Cliona Grant, Susan Price, Seth Thacker, Abdalrahman Zarzour, Frank Pucino, Gyorgy Csako, Cheryl Yarboro, Iain McInnes, Takashi Kuroiwa, Dimitrios Boumpas, Gabor Illei, Alan T. Remaley, V. Koneti Rao
Journal: Blood (2014)
TCT-333 Accuracy of lumen boundary extracted from coronary CTA for calcified and noncalcified plaques assessed using OCT data
Authors: Gilwoo Choi, Kenzo Uzu, Takayoshi Toba, Shumpei Mori, Tomofumi Takaya, Toshiro Shinke, Arjun Roy, Tran Nguyen, Sophie Khem, Charles A. Taylor, Hiromasa Otake
Journal: Journal of the American College of Cardiology (2015)
Reduced Intensity Versus Myelo-Ablative Conditioning Regimen before Allogeneic Hematopoietic Stem Cell Transplantation for Blastic Plasmacytoid Dendritic Cell Neoplasm: A Retrospective Study of the French Society of Bone Marrow Transplantation and Cell Therapy (SFGM-TC)
Authors: Mathieu Leclerc, Régis Peffault de Latour, Mauricette Michallet, Didier Blaise, Patrice Chevallier, Pierre-Simon Rohrlich, Pascal Turlure, Stéphanie Nguyen, Fabrice Jardin, Ibrahim Yakoub-Agha, Leila Moukhtari, Nicole Raus, Sébastien Maury
Journal: Blood (2015)
Malthus redux, and still blind in the same eye
Authors: Don Ross
Journal: Behavioral and Brain Sciences (2016)

Abstract Gowdy &amp; Krall (G&amp;K) essentially recapitulate Malthus's classic argument for ecological pessimism in modern biological dress. Their reasoning also reproduces Malthus's blindness to the implications of technological innovation. Agriculture might have suppressed human individualism as G&amp;K insist, but technology has tended to foster it. This complicates human ecological prospects in a non-Malthusian way, and it might additionally provide the resources for deliverance from disaster.
Phase II Study on Bortezomib (BTZ) in Multiple Relapsed or Refractory Pediatric Acute Lymphoblastic Leukemia (rALL): High Response Rate with a Modestly Intensive Regimen Including BTZ, Not Related to Pharmacokinetics
Authors: Gertjan J.L. Kaspers, Denise Niewerth, Bram Wilhelm, Satianand Ramnarain, Hans Berkhof, Valerie De Haas, Ron A.A. Mathôt, Andishe Attarbaschi, Andre Baruchel, Eveline S. de Bont, Franca Fagioli, Claudia Rossig, Thomas Klingebiel, Barbara De Moerloose, Brigitte Nelken, Giuseppe Palumbo, Dirk Reinhardt, Pierre Simon Rohrlich, Pauline Simon, Arend Stackelberg, C. Michel Zwaan
Journal: Blood (2015)
A Phase I Clinical Trial and Independent Patient-Derived Xenograft Study of Combined Targeted Treatment with Dacomitinib and Figitumumab in Advanced Solid Tumors
Authors: Emiliano Calvo, Jean-Charles Soria, Wen Wee Ma, Tao Wang, Rastilav Bahleda, Anthony W. Tolcher, Diana Gernhardt, Joseph O'Connell, Robert Millham, Nagdeep Giri, Michael J. Wick, Alex A. Adjei, Manuel Hidalgo
Journal: Clinical Cancer Research (2016)

Purpose: This phase I, open-label, single-arm trial assessed the safety and tolerability of dacomitinib-figitumumab combination therapy in patients with advanced solid tumors.Experimental Design: A standard 3 + 3 dose escalation/de-escalation design was utilized. Starting doses were figitumumab 20 mg/kg administered intravenously once every 3 weeks and dacomitinib 30 mg administered orally once daily. We also performed an independent study of the combination in patient-derived xenograft (avatar mouse) models of adenoid cystic carcinoma.Results: Of the 74 patients enrolled, the most common malignancies were non-small cell lung cancer (24.3%) and colorectal cancer (14.9%). The most common treatment-related adverse events in the 71 patients who received treatment across five dose levels were diarrhea (59.2%), mucosal inflammation (47.9%), and fatigue and acneiform dermatitis (45.1% each). The most common dose-limiting toxicity was mucosal inflammation. Dosing schedules of dacomitinib 10 or 15 mg daily plus figitumumab 20 mg/kg every 3 weeks after a figitumumab loading dose were tolerated by patients over multiple cycles and considered recommended doses for further evaluation. Objective responses were seen in patients with adenoid cystic carcinoma, ovarian carcinoma, and salivary gland cancer. Pharmacokinetic analysis did not show any significant drug-drug interaction. In the adenoid cystic carcinoma xenograft model, figitumumab exerted significant antitumor activity, whereas dacomitinib did not. Figitumumab-sensitive tumors showed downregulation of genes in the insulin-like growth factor receptor 1 pathway.Conclusions: Dacomitinib-figitumumab combination therapy was tolerable with significant dose reductions of both agents to less than the recommended single-agent phase II dose of each drug. Preliminary clinical activity was demonstrated in the potential target tumor adenoid cystic carcinoma. Clin Cancer Res; 23(5); 1177-85. ©2016 AACRSee related commentary by Sundar et al., p. 1123.
TCT-179 Comparison of Culprit-only versus Multi-vessel Percutaneous Coronary Intervention with 2nd Generation Drug- Eluting Stent in ST-elevation Myocardial Infarction: Data from INTERSTELLAR cohort
Authors: Sang-Don Park, Pyung Chun Oh, Hyun Woo Park, Ho-Jun Jang, Jeonggeun Moon, Tae-Hoon Kim, Sung Woo Kwon, Sung-Hee Shin, Jon Suh, Sung-Il Woo, Woong Chol Kang, Dae-Hyeok Kim, Jun Kwan
Journal: Journal of the American College of Cardiology (2015)
Effect of Sitagliptin on Kidney Function and Respective Cardiovascular Outcomes in Type 2 Diabetes: Outcomes From TECOS
Authors: Jan H. Cornel, George L. Bakris, Susanna R. Stevens, Michael Alvarsson, Willem A. Bax, Lee-Ming Chuang, Samuel S. Engel, Renato D. Lopes, Darren K. McGuire, Axel Riefflin, Helena Wachslicht Rodbard, Isaac Sinay, Tsvetalina Tankova, Julio Wainstein, Eric D. Peterson, Rury R. Holman
Journal: Diabetes Care (2016)

OBJECTIVE To evaluate chronic kidney disease (CKD) and cardiovascular outcomes in TECOS (Clinical trial reg. no. NCT00790205, clinicaltrials.gov) participants with type 2 diabetes and cardiovascular disease treated with sitagliptin, a dipeptidyl peptidase 4 inhibitor, according to baseline estimated glomerular filtration rate (eGFR). RESEARCH DESIGN AND METHODS We used data from 14,671 TECOS participants assigned in a double-blind design to receive sitagliptin or placebo added to existing therapy, while aiming for glycemic equipoise between groups. Cardiovascular and CKD outcomes were evaluated over a median period of 3 years, with participants categorized at baseline into eGFR stages 1, 2, 3a, and 3b (≥90, 60–89, 45–59, or 30–44 mL/min/1.73 m2, respectively). RESULTS Participants with eGFR stage 3b were older, were more often female, and had a longer duration of diabetes. Four-point major adverse cardiovascular event rates increased with lower baseline eGFR (3.52, 3.55, 5.74, and 7.34 events/100 patient-years for stages 1–3b, respectively). Corresponding adjusted hazard ratios for stages 2, 3a, and 3b versus stage 1 were 0.93 (95% CI 0.82–1.06), 1.28 (1.10–1.49), and 1.39 (1.13–1.72), respectively. Sitagliptin therapy was not associated with cardiovascular outcomes for any eGFR stage (interaction P values were all &amp;gt;0.44). Kidney function declined at the same rate in both treatment groups, with a marginally lower but constant eGFR difference (−1.3 mL/min/1.73 m2) in those participants who were assigned to sitagliptin. Treatment differences in these eGFR values remained after adjustment for region, baseline eGFR, baseline HbA1c, time of assessment, and within-study HbA1c levels. CONCLUSIONS Impaired kidney function is associated with worse cardiovascular outcomes. Sitagliptin has no clinically significant impact on cardiovascular or CKD outcomes, irrespective of baseline eGFR.
Does the risk of lymphoma in patients with RA treated with TNF inhibitors differ according to the histological subtype and the type of TNF inhibitor?
Authors: Gaetane Nocturne, Raphaele Seror, Xavier Mariette
Journal: Annals of the Rheumatic Diseases (2016)

We read with interest the paper by Mercer et al 1 focusing on the risk of lymphoma in patients included in the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis (BSRBR-RA) and treated with tumour necrosis factor inhibitors (TNFi). Based on data from a prospective cohort including >120 000 patient-years of exposure to TNFi or conventional synthetic disease-modifying drugs (csDMARDs), the authors pointed out that treatment with TNFi in patients with RA was not associated with an increased risk of lymphoma compared with csDMARD treatment. RA is associated with an increased risk of lymphoma, disease activity being the main risk factor of lymphoma occurrence.2 Thus, patients with RA treated with TNFi, which have more severely active disease, are supposed to have an increased baseline risk of lymphoma. In this context, the impact of TNFi themselves is unclear. They might decrease the risk of lymphoma over time by controlling activity of the disease. But they also might alter antitumour immunosurveillance and increase the risk of lymphoma as observed in post-transplant lymphoproliferative disease. Thus, large epidemiological studies focusing on the long-term safety of TNFi use as the one presented by Mercer et al are crucial. This important study, in line with results from large cohorts and registers,3 ,4 supports an overall absence of increased risk of lymphoma associated with …
A phase I study of TPI 287, a novel taxane, administered weekly in patients with advanced cancer
Authors: S. Silberman, J. H. Hwang, J. L. Marshall, T. Ahmed, M. Basche, A. L. Cohn, M. R. Modiano, G. Tapolsky, S. Yancik, L. Pugliese
Journal: Journal of Clinical Oncology (2008)

2536 Background: TPI 287 is a novel taxane designed to avoid drug efflux by mdr-1. Preclinically, TPI 287 demonstrated activity against multiple human tumor xenografts, including those expressing mdr-1 and resistant to other taxanes. Methods: This was a phase I dose escalation study of TPI 287 administered weekly for 3 weeks followed by 1 week off. Treatment cohorts consisted of 3 pts and were expanded to 6 pts if dose-limiting toxicity (DLT) was seen; pts could remain on study until the development of progressive disease or an intolerable adverse event. The MTD was defined as the dose at which < 2/3 of pts experienced DLT. Results: 48 pts (M:F 25:23, median age 60, range 24 - 86) were enrolled in 7 dose levels ranging from 7 - 185 mg/m2. Pts’ cancers included colorectal (14); pancreatic and ovarian (4 each); gastroesophageal, H&N, NSCLC, prostate, hepatobiliary (3 each); and 1 pt each with basal cell, breast, cervical, endometrial, melanoma, osteosarcoma, renal, SCLC, thymus and thyroid All pts received prior chemotherapy (median#: 4; range, 1 - 9). Pts on study received a median of 2 cycles of therapy (range 1–7). All pts had drug related adverse events, the most common being neuropathy (44%), fatigue (25%), and diarrhea (15%). DLTs consisted of 7 grade 3 and 1 grade 4 incidents of peripheral neuropathy, and 1 grade 3 neutropenia. One patient with NSCLC had a 57% response by RECIST; one patient with pancreatic cancer had a confirmed response by CA 19–9 (98%) sustained over four cycles with a 15% response by RECIST; and two patients (thyroid, colorectal) have had sustained stable disease for over 6 months (continuing on extension study). Peak plasma concentrations (Cmax) and area under the curve (AUC) were generally dose linear at the 3 highest doses administered, and similar to values reported for paclitaxel infused for 1 or 3 hours at clinically relevant dose levels ranging from 135 to 175 mg/m2. Conclusions: TPI 287 can be safely administered at a dose of 127 mg/m2 weekly for 3 weeks every 28 days. The DLTs consisted of neuropathy and neutropenia. Antitumor activity was seen in two pts with NSCLC and pancreatic cancers, respectively. PK is dose linear and predictable. Several phase II studies using TPI 287 at this dose and schedule have been initiated. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Expert Testimony Other Remuneration Tapestry Pharmaceuticals, Inc.
Inpatient Geriatric Assessment Detects Impairment Among Older Adults Receiving Induction Chemotherapy for Acute Myelogenous Leukemia.
Authors: Heidi D Klepin, Ann M Geiger, Jeff Williamson, Stephen Kritchevsky, Janet A Tooze, Leslie Renee Ellis, Denise Levitan, Scott Isom, Bayard L. Powell
Journal: Blood (2009)
18F-FDG PET/CT in Bladder Cancer
Authors: Luca Tagliabue, Giovanna Russo, Giovanni Lucignani
Journal: Clinical Nuclear Medicine (2016)

Urinary clearance of 18F-FDG and variability in bladder wall FDG uptake may hamper the interpretation and limit the use of FDG-PET/CT for imaging bladder tumors. Nevertheless, careful combined evaluation of both CT and FDG-PET images of the urinary tract can provide useful findings. We present 2 cases of bladder cancer detected by FDG-PET/CT. These cases suggest that FDG uptake can be indicative of malignancy in bladder cancer when viewed in conjunction with CT scans and that whole-body FDG-PET/CT scans should always be reviewed with particular attention to the urinary tract because abnormalities suggestive of bladder cancer can be found unexpectedly.
Use of changes in serum alkaline phosphatase to predict survival independent of PSA changes in men with castration-resistant prostate cancer and bone metastasis receiving chemotherapy: A retrospective analysis of the TAX327 trial.
Authors: G. R. Pond, G. Sonpavde, W. R. Berry, R. De Wit, A. J. Armstrong, M. A. Eisenberger, I. Tannock
Journal: Journal of Clinical Oncology (2010)

4637 Background: Whilebaseline serum alkaline phosphatase (ALP) appears to be prognostic for overall survival (OS) in men with metastatic castration-resistant prostate cancer (CRPC), the association of a change in ALP with OS in patients receiving chemotherapy is unknown. We evaluated retrospectively changes within 90 days in ALP in men with CRPC and bone metastasis treated with docetaxel or mitoxantrone in the TAX327 trial to determine whether they were associated with OS independent of PSA changes. Methods: Eligible patients for this analysis included those with bony metastatic disease, ALP ≥120 u/L (upper limit of normal) at baseline and having ≥2 post-therapy measurements of ALP available. Survival was estimated using the Kaplan-Meier method and prognostic ability of change in ALP was performed using Cox proportional hazards regression. Surrogacy was calculated by the Likelihood Reduction Factor. Results: 601 patients met the eligibility criteria. By day 90, 159 patients had ALP normalization (<120 u/L) and 442 patients did not normalize. Median survival from day 90 was significantly better amongst patients with normalization of ALP (18.6 months vs. 13.4 months, p<0.001). Normalization of ALP remained prognostic for OS after adjusting for PSA decline ≥30% by day 90 (HR 0.79, 95% CI=0.65-0.97, p=0.022). Any increase in ALP by day 90 was seen in 89 patients and was associated with significantly poorer median OS (11.8 vs. 16.3 months, HR 1.68, 95% CI= 1.32-2.13, p<0.001), with a trend toward worse survival with larger increases. Any increase in ALP remained prognostic for OS when adjusting for PSA increase ≥50% by day 90 (HR 1.69, 95% CI=1.33-2.14, p<0.001). However, ALP changes were not a surrogate for outcomes. Conclusions: For men with CRPC, bone metastasis and high baseline ALP receiving docetaxel or mitoxantrone chemotherapy, normalization of ALP by day 90 was predictive of better survival independent of ≥30% PSA declines. Any increase in ALP by day 90 was also predictive of poor survival independent of ≥50% PSA increase. Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration sanofi-aventis sanofi-aventis sanofi-aventis
Predictors and effect of delay in initiation of radiation therapy (RT) after breast-conserving surgery (BCS) in elderly women
Authors: R. S. Punglia, J. C. Weeks, B. A. Neville, C. C. Earle
Journal: Journal of Clinical Oncology (2008)

6515 Background: The influence of time from BCS to initiation of RT on treatment outcomes is controversial. We sought to study predictors of delay in initiating RT and the influence of delay on breast cancer recurrence in elderly women. Methods: Using the linked Surveillance, Epidemiology, and End Results-Medicare database, we analyzed 19,972 women with Stage 0, I or II breast cancer diagnosed between 1991 and 2002 and who received both BCS and RT but not chemotherapy. Multivariable logistic regression was used to investigate clinical and sociodemographic factors associated with delay in RT initiation. Cox proportional hazards models were used to study the influence of time to RT initiation on breast cancer recurrence. Results: Median time from last breast cancer surgery to initiation of RT was 28 days. Among the cohort, 22.2% of the women began RT greater than 6 weeks from their last surgery. In multivariate analysis increased likelihood of starting RT later than 6 weeks was associated with having positive lymph nodes (p<0.0001), higher Charlson score (p=0.028), history of low income (p=0.0006), Hispanic ethnicity (p<0.0001), non-white race (p<0.0001), later year of diagnosis (p<0.0001), and residence in a lower socioeconomic (p=0.027) or urban area (p=0.017), and in the northeast, midwest or west coast (p<0.0001). After controlling for significant clinical and other factors, RT initiation greater than 6 weeks from surgery was associated with an increase in local breast cancer recurrence (HR=1.25, p=0.016). Indeed, when modeled as a continuous variable, each extra day between surgery and RT initiation was associated with increased risk of recurrence (adjusted HR=1.005, p=0.0023). Conclusions: Our results indicate significant disparity in time to RT initiation among elderly women who receive BCS. Regions of the country known to have increased utilization of BCS had longer times to RT initiation, suggesting limitations in the capacity of RT delivery. We have also demonstrated an association between delay in RT initiation and increased local recurrence. Given the known negative impact of local recurrence in breast cancer on patient survival, mechanisms to ameliorate the disparities and policies regarding treatment wait times should be implemented. No significant financial relationships to disclose.
Biomimetic whitlockite inorganic nanoparticles-mediated in situ remodeling and rapid bone regeneration
Authors: Hwan D. Kim, Hae Lin Jang, Hyo-Yong Ahn, Hye Kyoung Lee, Jungha Park, Eun-seo Lee, Eunjee A. Lee, Yong-Hoon Jeong, Do-Gyoon Kim, Ki Tae Nam, Nathaniel S. Hwang
Journal: Biomaterials (2016)
Phase II study of lipiodol chemoembolization with cisplatin and thiotepa with oral thalidomide for primary liver cancer and liver metastases
Authors: L. G. Feun, A. Marini, A. Echenique, J. J. Guerra, J. M. Yrizarry, K. Stadtlander, N. Savaraj, L. Jeffers, C. Obrien, E. Schiff
Journal: Journal of Clinical Oncology (2004)

4137 Background: Lipiodol chemoembolization of the liver (LCE) can result in tumor shrinkage in part by causing abrupt devascularization and hypoxia in tumor-bearing regions. Regrowth of tumors is accompanied by neovascularity. Adding an antiangiogenesis agent like thalidomide after LCE may potentially improve the antitumor response. We have previously reported on LCE using cisplatin (DDP) and thiotepa(TT) in patients (pts). with unresectable liver tumors (LT) In this pilot trial we studied the feasibility of combining LCE with DDP and TT followed by oral thalidomide in pts with LT. Methods: Pts with LT with measurable disease by CT/MRI scan had LCE. DDP 100 mg/m2 and TT 24 mg/m2 were infused via hepatic artery over 15–20 min. On days 4–59 thalidomide was given at an initial dose of 100 mg po daily with weekly increments of 100 mg to a maximum of 400 mg daily. Followup CT/MRI scans were repeated every 2–3 months. LCE was repeated every 2–3 months in stable/responding pts. Results: 18 pts were entered into the study. Diagnoses included hepatoma ( HB 14 pts), ocular melanoma (3), and adenocarcinoma (1). 6 pts could not have embolization due to portal vein occlusion and received chemotherapy only. 12 pts had LCE. 9 pts had 1 course, 2 pts had 2 courses, and 1 pt had 4 courses of therapy. 5 pts had prior chemotherapy. All 12 pts with LCE were evaluable for response and toxicity. 2 HB pts had response 18 and 12 months. 1 melanoma pt had stable disease 5 months. Toxicity was reversible, usually mild and included abdominal pain, leukopenia and thrombocytopenia, nausea, fatigue, transient transaminase elevation, skin rash, and fever. Other toxicities include ototoxicity, and peripheral neuropathy. Conclusions: LCE with cisplatin and thiotepa followed by thalidomide is feasible and toxicity manageable. Durable responses observed in HB is encouraging and accrual is continuing. No significant financial relationships to disclose.
Metastatic uveal melanoma: Is there a role for conventional chemotherapy? A single experience based on 58 patients.
Authors: M. Plana, F. Pons Valladares, J. M. Caminal, J. Pera, I. C. Fernandes, F. J. Perez, X. Garcia del Muro, C. Gutierrez, L. Jimenez, J. M. Piulats
Journal: Journal of Clinical Oncology (2010)

e19006 Background: Uveal melanoma is a rare disease. Metastases develop in 6.5%-35% of the patients, most commonly in the liver. Metastatic uveal melanoma (MUM) survival is poor, with 5 to 7 months median survival. The aim of this study is to assess clinical characteristics and survival in patients with MUM. Methods: We reviewed retrospectively all patients with MUM diagnosed between 1990 and end 2008 at our institution. Results: We analyzed a total of 58 patients with a median age of 61 years (31-84). Median time for the development of metastases was 25,63 months (0.17-102.43). 56 patients had hepatic involvement, 63.8% bilobar and ≥ 7 hepatic lesions on 51.7%. Sixteen patients (27.6%) had two or more organs involved. Six patients (10.71%) were treated with surgery, 25 patients (44.67%) received systemic chemotherapy, and 23 (41.07%) had best supportive care (BSC). The median overall survival (OS) for the total of the patients was 10,83 months (6.92-14.74; 95%CI). Patients with local metastatic treatment were not assessable for individual OS. Patients who did chemotherapy presented 10,83 months (5.35-16.308; CI 95%) median OS survival and the patients without treatment had an OS of 8,033 months (2.46-13.61; 95%CI). There were more patients with poor survival characteristics such as worst ECOG in the BSC group. Only ≥ 7 hepatic lesions was significative in the univariate analysis. ECOG and ≥ 7 hepatic lesions were significative in the multivariate test. Treatment with chemotherapy was not statistically significant in the univariate neither in the multivariate analysis. Conclusions: Overall survival was poor in treated and BSC patients. Differences on survival are more likely related to patient characteristics, such as ECOG, rather than chemotherapy effect. Patients with MUM should be included in clinical trials evaluating other options with newer agents. No significant financial relationships to disclose.